JMJD2A Antibody (D-9): sc-271210

JMJD2A Antibody (D-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects JMJD2A of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-JMJD2A antibody (D-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. JMJD2A, also known as jumonji domain containing 2A, is a 1,064 amino acid protein encoded by the human gene JMJD2A and is a member of the JHDM3 histone demethylase family. JMJD2A features a complex structure that includes one JmjC domain, one JmjN domain, two PHD-type zinc fingers, and two Tudor domains, which are crucial for enzymatic activity. JMJD2A functions primarily as a histone demethylase, specifically targeting the demethylation of tri-methylated lysine residues at positions 9 and 36 of histone H3, thereby playing a pivotal role in regulating the histone code. This selective demethylation is essential for various cellular processes, including transcriptional regulation, as JMJD2A influences chromatin structure and gene expression. JMJD2A does not demethylate histone H3 at lysine 4 or lysine 27, nor histone H4 at lysine 20, which underscores specificity and importance in epigenetic regulation. The demethylation process generates formaldehyde and succinate, further linking JMJD2A to metabolic pathways. JMJD2A is involved in transcriptional repression of ASCL2 and E2F-responsive promoters through recruitment of histone deacetylases and nuclear receptor corepressor 1 (NCOR1), highlighting a role in gene silencing. As a ubiquitously expressed nuclear protein, JMJD2A is integral to maintaining proper gene expression and cellular function across various tissues.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

JMJD2A Antibody (D-9) References:

1. Identification and characterization of JMJD2 family genes in silico.  |  Katoh, M. and Katoh, M. 2004. Int J Oncol. 24: 1623-8. PMID: 15138608
2. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.  |  Gray, SG., et al. 2005. J Biol Chem. 280: 28507-18. PMID: 15927959
3. JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2).  |  Zhang, D., et al. 2005. Mol Cell Biol. 25: 6404-14. PMID: 16024779
4. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A.  |  Huang, Y., et al. 2006. Science. 312: 748-51. PMID: 16601153
5. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.  |  Whetstine, JR., et al. 2006. Cell. 125: 467-81. PMID: 16603238
6. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity.  |  Ng, SS., et al. 2007. Nature. 448: 87-91. PMID: 17589501
7. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor.  |  Lee, J., et al. 2008. Nat Struct Mol Biol. 15: 109-11. PMID: 18084306
8. JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.  |  Su, Y., et al. 2017. BMC Cancer. 17: 477. PMID: 28693517
9. JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.  |  Nakagawa, T., et al. 2020. Gastric Cancer. 23: 426-436. PMID: 31677131
10. Engineering human JMJD2A tudor domains for an improved understanding of histone peptide recognition.  |  Parkinson, J., et al. 2023. Proteins. 91: 32-46. PMID: 35927178
11. JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.  |  Cai, X., et al. 2023. BMC Cancer. 23: 423. PMID: 37165308
12. SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A.  |  Gu, R., et al. 2023. JCI Insight. 8: PMID: 37870957

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-JMJD2A Antibody (D-9) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-JMJD2A Antibody (D-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

JMJD2A Antibody (D-9) Specifications

Alternate Product Name: JMJD2A

Product Clone Name: D-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 196-238

Epitope Target: JMJD2A

Epitope Species: human

Product Reactivity/Detection: JMJD2A

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine and bovine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for JMJD2A Antibody (D-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin